Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
No. If the algorithm determines 2 calibrations/day are needed to maintain the most accurate readings possible, the user will be notified. The best way for a user to support system accuracy is to calibrate as prompted and to always calibrate the system using only a fingerstick blood sample. DO NOT calibrate at times when glucose may be rapidly changing (e.g., after meals, after dosing insulin). DO NOT use a blood glucose reading from an alternative site (such as forearm or palm) to calibrate the system.
The sensor requires a 24-hour Warm-Up Phase to stabilize in your body before glucose values will be collected by the smart transmitter. During the Warm-Up Phase, you do not need to wear the smart transmitter. If you decide to wear the smart transmitter over the sensor during this time, you will receive a message on the app indicating the Warm-Up Phase is in progress. Once the Warm-Up Phase is complete, turn ON the smart transmitter and place it over the sensor with the Eversense® adhesive patch. The system will prompt you to calibrate using the app.
The Eversense® E3 Smart Transmitter sends a glucose reading to the App every 5 minutes.
When your mobile device is locked, or the App is running in the background, the alerts are recorded and kept active until you open the Eversense® App. Once the App is opened, the previous alerts will appear and allow you to dismiss them. When this occurs in the future, check the time stamp on the alert to confirm when the alert happened.
The Eversense® E3 Smart Transmitter will vibrate and the app will provide a “Transmitter Disconnected” notification every 30 minutes, and/or a status bar message, until the app is launched or the smart transmitter is reconnected. Once the connection is re-established, the data collected will sync with the mobile app and the graph will fill in.
Glucose Targets are the low and high levels of the range you are aiming for throughout the day. These settings are used in the app to indicate when glucose values are in your target range.
Note: Target range values must be set within alert range values. Do not change your glucose alert levels without consulting with your health care professional.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060